PTCT PTC THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1070081 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-35.1%
TTM net income YoY-114.1%
TTM EPS YoY-115.5%
Revenue 3-yr CAGR13.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin12.8%
Net margin-9.2%
FCF margin0.2%
EBITDA margin18.1%
Returns
ROE—
ROA-3.6%
ROIC (approx.)—
Asset turnover0.39x
Leverage & solvency
Liabilities / assets106.0%
Debt / equity—
Current ratio3.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.10x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.73B | $806.78M | $937.82M | $698.80M | $538.59M |
| R&D expense | $455.25M | $534.48M | $666.56M | $651.50M | $540.68M |
| SG&A expense | $347.14M | $300.91M | $332.54M | $326.00M | $285.77M |
| Operating income | $866.93M | -$302.57M | -$439.50M | -$447.41M | -$374.44M |
| Pretax income | $696.62M | -$363.12M | -$696.11M | -$587.49M | -$518.34M |
| Income tax | $13.97M | $176,000 | -$69.51M | -$28.47M | $5.56M |
| Net income | $682.64M | -$363.30M | -$626.60M | -$559.02M | -$523.90M |
| EBITDA | $905.75M | -$226.91M | -$202.91M | -$318.57M | -$310.31M |
| EPS (basic) | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 |
| EPS (diluted) | 7.78 | -4.73 | -8.37 | -7.79 | -7.43 |
| Weighted avg. shares (diluted) | 88.31M | 76.85M | 74.84M | 71.73M | 70.47M |
| Balance sheet | |||||
| Cash & equivalents | $984.65M | $795.32M | $610.28M | $295.93M | $197.22M |
| Short-term investments | $960.72M | $359.99M | $282.74M | $130.87M | $583.66M |
| Receivables | $181.62M | $158.55M | $160.82M | $155.61M | $110.45M |
| Inventory | $79.65M | $23.19M | $30.58M | $21.81M | $15.86M |
| Current assets | $2.27B | $1.37B | $1.22B | $693.78M | $954.37M |
| PP&E, net | $55.37M | $60.97M | $87.09M | $72.59M | $52.59M |
| Goodwill | $82.34M | $82.34M | $82.34M | $82.34M | $82.34M |
| Intangibles | $388.75M | $118.79M | $379.50M | $705.89M | $724.84M |
| Total assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B |
| Current liabilities | $968.43M | $580.98M | $603.10M | $406.24M | $509.35M |
| Short-term debt | $286.63M | — | — | — | $149.54M |
| Long-term debt | — | $285.41M | $284.21M | $571.72M | $281.89M |
| Total debt | — | $285.41M | $284.21M | $571.72M | $431.43M |
| Total liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B |
| Shareholders' equity | -$205.31M | -$1.10B | -$818.55M | -$347.09M | $1.44M |
| Net debt | — | -$509.90M | -$326.07M | $275.80M | $234.22M |
| Shares outstanding | 81.47M | 77.70M | 75.71M | 73.10M | 70.83M |
| Cash flow statement | |||||
| Operating cash flow | $711.20M | -$107.69M | -$158.42M | -$356.65M | -$251.33M |
| Capital expenditure | $8.86M | $6.50M | $28.44M | $32.02M | $28.21M |
| Free cash flow | $702.34M | -$114.19M | -$186.86M | -$388.67M | -$279.55M |
| Investing cash flow | -$861.98M | $44.18M | -$176.74M | $290.18M | $219.18M |
| Financing cash flow | $331.09M | $255.87M | $646.40M | $167.95M | $20.88M |
| Depreciation & amortization | $38.81M | $75.66M | $236.59M | $128.84M | $64.13M |
| Stock-based compensation | $74.55M | $74.61M | $101.64M | $110.33M | $103.51M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.